Thursday - January 8, 2026
Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones
January 06, 2026
BOSTON, Massachusetts, Jan. 6 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Goodwin Guides Royalty Pharma on Acquisition of Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

*

The Life Sciences team guided Royalty Pharma plc (Nasdaq: RPRX) on the acquisition of the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 mill . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products